Melanoma & Skin Cancer | Specialty

The OncLive Melanoma & Skin Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of skin cancers, including melanoma, basal cell carcinoma, and more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in melanoma and other skin cancers.

Managing BCR-ABL Inhibitor Associated Skin Rash

October 27th 2013

Managing Angiogenesis Inhibitor Related Skin Toxicity

October 27th 2013

Anticipatory Coping in Patients Treated With EGFR Inhibitors

October 27th 2013

Managing EGFR Inhibitor Associated Skin Toxicity

October 27th 2013

Dr. Sondak on Personalizing the Treatment of Melanoma

October 24th 2013

Vernon K. Sondak, MD, chair of the Department of Cutaneous Oncology at Moffitt Cancer Center in Tampa, Florida, talks about personalized medicine when treating patients with melanoma.

Dr. Lewis on New and Emerging Treatments for Melanoma

October 21st 2013

Karl Lewis, MD, medical oncologist, associate professor, University of Colorado, discusses new and emerging treatments for metastatic melanoma

Dr. Kudchadkar Discusses Melanoma Testing

October 17th 2013

Ragini Kudchadkar, MD, assistant professor, medical oncology, Moffitt Cancer Center, discusses testing for melanoma.

Advances in Metastatic Melanoma Bring Price Competition, Redefinition of Value, and Likely Increased Payer Utilization Management

October 14th 2013

Traditionally, payers have been increasingly more proactive in their management of drug expenditures in cancers with the highest prevalence and with the more costly therapeutics.

Dr. Weber on Genetic Testing for Patients with Melanoma

October 14th 2013

Jeffrey S. Weber, MD, PhD, medical oncologist, Department of Cutaneous Oncology, director, Donald A. Adam Comprehensive Melanoma Research Center, Moffitt Cancer Center, discusses testing for genetic mutations in patients with melanoma.

Dr. Magliocco on Pathologists in the Treatment of Melanoma

October 10th 2013

Anthony M. Magliocco, MD, chair of pathology, executive director of esoteric labs at Moffitt Cancer Center, discusses the role of the pathologist in the treatment of a patient with melanoma.

Dr. Hamid on Immune Therapy in Melanoma

October 8th 2013

Omid Hamid, MD, discusses using immune therapy to treat patients with melanoma.

Redheads and Melanoma

October 7th 2013

Underlying mechanism for increased risk now defined.

Dr. Kudchadkar on BRAF and MEK Inhibitors in Melanoma

October 4th 2013

Ragini Kudchadkar, MD, assistant professor, medical oncology, Moffitt Cancer Center, discusses the benefits of combining BRAF and MEK inhibitors when treating melanoma.

Pooled Analysis Reinforces Long-Term Survival Benefit With Ipilimumab

October 2nd 2013

Results from a pooled analysis of data from 12 studies has demonstrated a long-term survival benefit that extends through at least 10 years for patients with advanced melanoma treated with ipilimumab.

Dr. Hudis on the Optimism Surrounding Immunotherapy

September 27th 2013

Clifford A. Hudis, MD, ASCO president, chief, Breast Cancer Medicine Service, Attending Physician, Memorial Sloan-Kettering Cancer Center, discusses his optimism surrounding immunotherapy for cancer care.

Dr. Carvajal on the Design of a Trial in Uveal Melanoma

September 25th 2013

Richard D. Carvajal, MD, medical oncologist, Memorial Sloan-Kettering Cancer Center, describes the design of a phase II study of selumetinib versus temozolomide in uveal melanoma with GNAQ/GNA11 mutations.

Dr. Sosman on the Mechanism of Action of Ipilimumab

September 24th 2013

Jeffrey A. Sosman, MD, professor of medicine, Director, Melanoma and Tumor Immunotherapy Program, Vanderbilt University School of Medicine, Vanderbilt-Ingram Cancer Center, describes the mechanism of action of ipilimumab in patients with melanoma.

Dabrafenib and Trametinib Combination Granted Priority Review Designation by FDA

September 16th 2013

The FDA has granted Priority Review designation to dabrafenib (Tafinlar) and trametinib (Mekinist) as a combination treatment for patients with unresectable or metastatic melanoma with a BRAFV600E/K mutation.

Investigational Vaccine Fails to Extend Disease-Free Survival in Certain Patients with Advanced Melanoma

September 5th 2013

The investigational MAGE-A3 immunotherapeutic did not significantly extend disease-free survival (DFS) in certain patients with postsurgical melanoma when compared with a placebo in a phase III study.

Novel Agents Revolutionize Melanoma Treatment

September 5th 2013

Until recently, the cornerstone of therapy for metastatic melanoma had been chemotherapy with dacarbazine (DTIC) and immunotherapy with high-dose interleukin-2 (HD IL-2) or interferon-Î± (IFN-Î±).